Kisspeptin Peptide: Benefits, Dosage & Real Science

One gene decides whether puberty happens at all. Not testosterone, not estrogen, not even the pituitary gland. A single peptide sitting above all of them in the chain of command, called kisspeptin, is the switch that starts the entire process. Lose it from birth and puberty never begins. Get a rare mutation that leaves it stuck in the on position, and puberty can start years early.

That alone makes it one of the more remarkable discoveries in reproductive biology. What makes it relevant to a peptide guide is what came after. Researchers at Imperial College London have since given it to men and women in controlled trials and watched sexual desire circuits activate on brain scans. They have used it to trigger egg maturation during IVF. They have used it to restart a reproductive system that shut down under stress.

BrainFlow Newsletter

Want to live forever? Thought so.

One email every Friday — the best on supplements, longevity, and biohacking, cut down to what actually works. No spam. Unsubscribe anytime.

Email address Subscribe

No spam. Your privacy is important to us.

This guide covers what kisspeptin does in real human trials, broken out by sex, plus the dosing and scheduling questions people search for most. It also covers the one thing worth knowing before you start. With this compound, spacing matters more than amount.

Quick note if you already know you want to try this. Amino Club’s kisspeptin is tested 7 times with full COAs published, which matters more than usual here given how small and fast-degrading this peptide is. The 10mg runs $49.99 and drops to about $39.99 with code BRAINFLOW. Now, the full picture.

What Kisspeptin Really Is

Kisspeptin is not one molecule. It is a family of related peptides, all cut from the same larger protein made by the KISS1 gene. The full-length version, 54 amino acids long, is kisspeptin-54, sometimes called metastin in older papers. Shorter active fragments exist too, kisspeptin-14, kisspeptin-13, and kisspeptin-10, all sharing the same tail end that does the actual work of activating the receptor.

Kisspeptin-10 vs Kisspeptin-54

This is the single most useful distinction on this page, and almost nobody selling the compound explains it clearly. Kisspeptin-10 is what gets sold as a research peptide, the shortest active fragment, cheap to synthesize, and cleared from your bloodstream in minutes. Its sequence is Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2, ten amino acids, verified against PubChem.

Kisspeptin-54 is the full-length form, and it is what researchers used in nearly every trial in this guide. The extra 44 amino acids are not just padding. Kisspeptin-54’s longer half-life is a real part of why a single injection in a trial setting produced results that a fragment clearing in four minutes may struggle to match on its own.

• Kisspeptin-10: 10 amino acids, roughly a 4 minute half-life, the form almost every vendor sells
• Kisspeptin-54: 54 amino acids, roughly a 27 minute half-life, the form used in nearly every human trial

One more identity question worth settling up front, because it causes real confusion. Kisspeptin is not PT-141. Both get marketed as libido peptides, but PT-141 works through melanocortin receptors in the brain with no direct link to the reproductive hormone axis, while kisspeptin works through its own receptor sitting directly on the neurons that control that axis. PT-141 completed Phase 3 trials and was FDA-approved in 2019 as Vyleesi. Kisspeptin has never gone through that process for anything.

The name itself has an odd backstory. The gene was discovered in 1996 in Hershey, Pennsylvania, by researchers hunting for genes that suppress melanoma from spreading. They found one and named its peptide metastin. Nobody connected it to reproduction until 2003, when researchers discovered that people born with a broken receptor for this peptide never went through puberty. A field that started in cancer research became one of the most active corners of reproductive endocrinology almost overnight.

The Hypothalamic-Pituitary-Gonadal Axis, Simply

Reproduction runs on a chain of command. The hypothalamus releases a hormone called GnRH in short pulses. Those pulses tell the pituitary gland to release LH and FSH, which travel through the blood and trigger the ovaries or testes to produce estrogen and eggs, or testosterone and sperm.

Doctors call this the hypothalamic-pituitary-gonadal axis, or HPG axis. It only works if GnRH arrives in pulses rather than a steady stream. A constant flood shuts the whole system down instead, which is the actual basis for the drugs used in chemical castration for prostate cancer.

Kisspeptin sits one level above GnRH, acting as the pacemaker that decides when those neurons fire. That single fact explains why losing kisspeptin signaling stops puberty from starting, and why certain mutations that leave the receptor overactive cause puberty to arrive years early.

What makes the kisspeptin neurons clever is what they check before sending that signal at all. They track body fat, energy availability, and stress, and they hold the signal back if the body does not look like it has enough in reserve to support pregnancy or sperm production. That is exactly why severe calorie restriction, very low body fat, and chronic stress can shut a woman’s cycle down entirely, a condition called hypothalamic amenorrhea. The neurons are not malfunctioning there. They are doing precisely what they evolved to do.

Calling kisspeptin a master switch is fair, with one catch. A switch only works if the wiring downstream is intact. Kisspeptin can turn the system on. It cannot fix a pituitary or gonads that are not functioning, and it is not a general hormone booster in the way that phrase sometimes implies.

How Kisspeptin Works

Two separate groups of kisspeptin neurons do most of the work. One, in a region called the arcuate nucleus, generates the steady pulses that drive GnRH release hour to hour. The other generates the single large surge that triggers ovulation each cycle. Both act on the same receptor, KISS1R, sitting on GnRH neurons, and binding it sets off a signaling cascade that makes those neurons fire.

That firing cascades downstream exactly as the HPG axis explanation above predicts. In a landmark study, six healthy men received a 90 minute IV infusion of kisspeptin-54, and LH roughly doubled compared to a saline infusion, with FSH and testosterone both rising significantly too. A separate study using the shorter kisspeptin-10 fragment as a single injection found LH rose in a dose-dependent way, peaking at a specific middle dose and, oddly, rising less at the highest dose tested.

That non-linear pattern is worth remembering. It shows up again below, and it is an early clue about how this particular receptor behaves under different types of stimulation.

Kisspeptin does something else that has nothing to do with LH or FSH. Brain imaging out of Imperial College London has found that kisspeptin infusions change activity in the limbic system, the part of the brain tied to emotional processing and sexual arousal, in ways that appear at least partly independent of the hormone cascade above. That is an unusual finding for a reproductive hormone, and it sets up most of what the next section covers.

Why hitting it more often can backfire

This is the part almost nobody selling kisspeptin explains, and it matters more than any benefit claim in this guide. The HPG axis is built to respond to a pulsing signal, not a constant one. Continuous or overly frequent activation of the kisspeptin receptor can desensitize it, meaning the same signal stops producing the same response, or reverses it entirely.

A longer-acting kisspeptin-receptor drug called TAK-448 proved this directly. Instead of raising testosterone the way a single dose does, continuous infusion drove testosterone down below the level normally seen after surgical castration by around the eighth day. The receptor did not fail. It behaved exactly the way continuously stimulated hormone receptors tend to, and the system shut itself down in response to a signal that would not stop.

Every positive result in this guide came from a single dose or a short, monitored infusion. Nobody has published data on daily home injections, and the pharmacology gives a real reason to think repeating it could work against you rather than simply do nothing.

What the Human Trials Show

What follows is exactly what kisspeptin has been shown to do in real people, broken down by who was studied and how.

Arousal in men

Twenty-nine healthy men received a kisspeptin infusion while researchers tracked brain activity in response to sexual and romantic images. Activity rose in regions tied to arousal and attraction, and the men separately reported less negative mood during the session.

A later, more clinical trial went further. Researchers recruited men diagnosed with hypoactive sexual desire disorder and gave them a 75 minute infusion of kisspeptin-54. Physical arousal in response to sexual content rose by up to 56 percent more than with placebo, and the men reported significantly more happiness about sex afterward. Testosterone and cortisol did not change during that short window, which supports the idea that this effect runs through the brain’s sexual-processing circuitry rather than a hormone shift.

Arousal in women

Most competing articles on this topic mention only the men’s research. That is a real gap, because Imperial College ran a matching study in women. Thirty-two premenopausal women with the same diagnosis went through a crossover trial, each receiving kisspeptin and placebo on separate visits.

Brain scans showed kisspeptin modulated activity in the same sexual and attraction-processing networks seen in the men’s study. This is one of the only compounds in the entire research-peptide world where an effect on sexual desire has been separately confirmed in both sexes, rather than assumed to transfer from one to the other.

Fertility and IVF

Standard IVF protocols trigger the final maturation of eggs using hCG or a GnRH agonist, both carrying real risk of a dangerous complication called ovarian hyperstimulation syndrome, or OHSS, especially in women who respond strongly to fertility drugs. Kisspeptin-54 was tested as an alternative trigger in exactly that high-risk group.

In a trial of 60 women, a single injection produced egg maturation in 95 percent of cycles, and not one woman developed moderate, severe, or critical OHSS. Live birth rates per embryo transfer reached as high as 62 percent at the higher end of the dose range. A follow-up trial found that a second dose raised the share of women getting a strong egg yield from 45 percent to 71 percent.

This is arguably the single strongest, most clinically useful finding in the whole kisspeptin research program, and it barely gets a mention on pages selling it as a libido or testosterone peptide.

Restarting a shut-down cycle

When a woman’s cycle stops due to under-eating, over-exercising, or chronic stress, her kisspeptin signaling has effectively gone quiet, the exact gatekeeper mechanism described earlier in this guide. Researchers gave five women with this condition a continuous kisspeptin-54 infusion and successfully restored a normal LH pulsing pattern.

The same researchers were explicit that the benefit fades under chronic dosing, since the receptor desensitizes over time. That finding ties directly back to the warning earlier in this guide, from a completely separate patient population.

What it does not do

A few other claims circulate that deserve a quick, honest answer rather than their own section. On appetite, a kisspeptin infusion changed how healthy men’s brains responded to pictures of food without changing how much they ate afterward. Separate research in women with overweight or obesity has looked at similar questions with more mixed results so far.

On puberty, the genetics linking kisspeptin to its onset are about as solid as human genetics gets, but that describes what happens when the system is congenitally absent or overactive from birth. It says nothing about supplementing kisspeptin as an adult, and it should never be read as implying anything about puberty timing later in life. On longevity and general anti-aging claims, there is no human data testing kisspeptin for either purpose in anyone, healthy or otherwise.

Kisspeptin Compared to Other Options

Kisspeptin does not replace any of these. It sits in a different evidence category entirely, small human trials in monitored research settings rather than large approved-drug programs, and none of these options have been tested against it head to head.

Kisspeptin Dosage in Research

Because people search for kisspeptin dosage, here is the real picture. There is a number almost everyone lands on, and a scheduling question that matters more than the number itself.

The number is 100 micrograms per injection. It is not random. It sits close to the roughly 1 microgram per kilogram dose that produced the strongest LH response in a bolus study of healthy men, the same study where going higher produced less of an effect instead. More is not the goal here. Landing in that range is.

Frequency is where the strongest evidence sits. A trial in women with hypothalamic amenorrhea compared twice-daily against twice-weekly kisspeptin-54. Twice daily wiped out the FSH response almost entirely by day two. Twice weekly held up, and a follow-on study using that same twice-weekly schedule kept LH and FSH elevated across a full eight weeks. Space it out, and the receptor keeps responding. Hit it daily, and it taps out fast.

• Common protocol: around 100mcg per injection, subcutaneous, 2 to 3 times a week on non-consecutive days
• The rule that matters most: frequency over amount, exactly what the twice-weekly trial above demonstrates
• Cycling: a few weeks on, then time off, is the pattern that shows up most in community discussion
• Route: subcutaneous, matching both common practice and most of the human trials in this guide

Nobody has run that exact combination, kisspeptin-10, subcutaneous, 100mcg, a few times weekly, as a formal trial. The dose logic and the frequency logic are each backed individually by real human data. Putting them together this way has not itself been tested. That is not a reason to panic. It is the reason this stays information, not instruction.

For readers who want the underlying research protocols themselves, here is exactly what was used in the studies referenced throughout this guide:

• HPG axis stimulation in men: kisspeptin-54 as a continuous IV infusion over 90 minutes
• LH bolus response: kisspeptin-10 as a single IV injection, peaking around 1mcg/kg
• Sexual arousal studies, men and women: kisspeptin-54 as a 75 minute IV infusion in both HSDD trials
• IVF egg-maturation trigger: kisspeptin-54 as a single subcutaneous injection, dosed by body weight under fertility-specialist supervision
• Hypothalamic amenorrhea, sustained response: kisspeptin-54 subcutaneous, twice weekly, the schedule referenced above

Route matters too. Every trial that produced a clear result used IV or supervised subcutaneous injection. There is no meaningful oral or nasal data, and given how peptides this size typically fare in the digestive tract, be skeptical of anything claiming otherwise.

Kisspeptin-10 Reconstitution and Concentration Math

Reconstitution math is simply concentration math. It does not establish whether a product should be used or what dose is appropriate. What follows is arithmetic, calibrated to the 100mcg range covered above, nothing more.

One milligram equals 1,000 micrograms. Concentration in milligrams per milliliter equals the total milligrams in the vial divided by the milliliters of liquid added. On a standard U-100 insulin syringe, 100 units equals 1 milliliter, so one unit equals 0.01 mL.

Read that table as arithmetic, not advice. A 5mg vial mixed with 2.5mL of water works out to 2mg/mL, which puts a 100mcg dose at a clean 5 units on an insulin syringe, easy to read and hard to misjudge. Add more water and that same 100mcg spreads across more units, which some people prefer for a steadier draw.

The mistakes that show up constantly include treating the total milligrams in a vial as a single dose, mixing up milligrams and micrograms by a factor of a thousand, assuming a syringe unit is a fixed amount regardless of concentration, and ignoring that kisspeptin-10 degrades quickly without proper cold storage.

Side Effects and Safety

In the actual clinical trials, kisspeptin’s short-term safety record was reassuringly plain. Reported effects included mild flushing, headache, and occasional nausea, all transient. In the IVF trigger trials specifically, kisspeptin was chosen precisely because it caused dramatically less OHSS than the standard trigger drugs, meaning it was the safer option in that context, not a riskier one.

The desensitization risk covered earlier in this guide is the safety point worth carrying forward here. Space doses out and the evidence supports it. Cluster them too close together, or push the amount too high, and the same receptor that responds well can stop responding, or worse.

Kisspeptin’s history as a cancer-metastasis suppressor gene deserves a plain mention rather than either hype or silence. In cell and animal models, KISS1 has generally shown a tumor-suppressive association. That is interesting biology on its own, and it is not evidence either way about what taking exogenous kisspeptin does to cancer risk in a person. Treat it as an open question, not a settled benefit or a settled danger.

Nobody has studied kisspeptin in pregnancy, breastfeeding, or adolescents, and given its direct role in triggering puberty, that last group has no business near it outside a supervised research setting. And as with any research-market peptide, there is a risk that has nothing to do with the compound itself. Unverified vials can carry the wrong material, the wrong concentration, or contamination, entirely separate from anything the trials measured.

Who Should Steer Clear

Anyone pregnant or breastfeeding, since there is no safety data at all. Anyone under 18, given kisspeptin’s direct role in triggering puberty. Anyone with a hormone-sensitive cancer history should talk to their oncologist first, given the unresolved, two-sided research on KISS1 and tumor biology.

And anyone hoping this replaces a fertility specialist, an endocrinologist, or an approved treatment like PT-141 or testosterone therapy should know that kisspeptin has never been tested head to head against any of them outside a research setting.

Legal and Regulatory Status

Kisspeptin and kisspeptin-10 are not FDA-approved for any indication. No new drug application has been approved for either form. FDA’s Pharmacy Compounding Advisory Committee reviewed kisspeptin-10 for the treatment of secondary hypogonadism in men at its October 29, 2024 meeting, alongside ibutamoren, ipamorelin, and L-theanine, and voted against adding it to the approved compounding list. US pharmacies cannot legally compound it into a prescription product as a result, even off-label.

The FDA has flagged specific concerns, including incomplete characterization of the substance, the potential for an immune response against it, the same desensitization issue covered throughout this guide, and a signal in animal data suggesting it might promote plaque buildup in blood vessels. None of these are settled human findings, but together they explain why it remains unapproved.

Longer-acting kisspeptin-receptor drugs are in earlier-stage pharmaceutical development for female reproductive conditions, but nothing has reached approval. Kisspeptin is not a dietary supplement ingredient and cannot legally be marketed as one. It is sold strictly as a research chemical, and any vendor making fertility, libido, or hormone-treatment claims about it is operating in a legal gray zone at best.

Athletes should also know that LH and the factors that trigger its release are prohibited substances under anti-doping rules, directly relevant given kisspeptin’s mechanism.

What People Stack Kisspeptin With

Community stacking discussion follows predictable logic, and almost none of it has been formally tested. People combine kisspeptin with PT-141, hoping two different libido mechanisms add up. They combine it with TRT protocols, hoping to keep some natural axis activity going alongside exogenous testosterone. They combine it with hCG or gonadorelin on the theory that hitting the axis from multiple angles works better than one.

The TRT combination deserves a specific reality check. Exogenous testosterone suppresses the HPG axis by design, telling the brain there is already enough hormone in circulation. Kisspeptin cannot override that feedback signal from outside the loop it is trying to activate, so stacking it with TRT is unlikely to do what people hope, and nobody has studied the combination to confirm it either way.

The broader caution applies here too. Layering multiple unstudied compounds makes it impossible to know which one is doing anything, including which one might be causing a side effect.

What Users Report

Treat everything here as anecdote. Community discussion on TRT and biohacking forums splits fairly evenly between enthusiasm and skepticism. People reporting a noticeable libido or mood lift usually describe daily or twice-daily subcutaneous injections around 100 micrograms.

The more scientifically literate corners of these same communities push back constantly on the two points raised throughout this guide. The roughly four minute half-life makes once-daily dosing pharmacologically questionable, and repeated dosing carries a real desensitization risk nobody has ruled out. Confusion between kisspeptin and PT-141, and between kisspeptin-10 and kisspeptin-54, shows up in nearly every thread, along with product-quality complaints and the absence of any bloodwork confirming what a given protocol is doing at all.

Where to Buy Kisspeptin

Sourcing matters enormously here. Kisspeptin-10 is small and fast-degrading, and identity and purity issues are common across this market. Buy only from a vendor that publishes real third-party certificates of analysis, and treat anything sold as kisspeptin as strictly research-use-only material, not equivalent to what was used in any trial in this guide.

Our pick is Amino Club’s kisspeptin. Every batch goes through 7 rounds of third-party testing with full COAs published, more verification than most of this market offers. 10mg is $49.99 and comes to about $39.99 with code BRAINFLOW for 20 percent off.

Kisspeptin FAQ

Is kisspeptin the same as kisspeptin-10?

Kisspeptin is the umbrella term for the whole peptide family. Kisspeptin-10 is the shortest active fragment and the one almost always sold as a research peptide. Kisspeptin-54, the full-length form, is what nearly every human trial used.

Is kisspeptin the same as PT-141?

No. Both get marketed as libido peptides, but kisspeptin works through the KISS1R receptor and the reproductive hormone axis, while PT-141 works through unrelated melanocortin receptors. PT-141 is FDA-approved for one indication. Kisspeptin is not approved for anything.

Does kisspeptin increase libido?

In controlled trials, yes, measurably, in both men and women, using brain imaging and physical arousal measures. Every one of those results came from a single monitored infusion, not repeated home dosing, so that gap matters when setting expectations.

Does kisspeptin raise testosterone?

Acutely, in monitored infusion studies, yes. There is no evidence either way for what repeated daily injections do, and the desensitization pattern seen with continuous dosing of a related compound is a real reason for caution.

Is kisspeptin FDA approved?

No. It is not approved for any indication, and it is not on the FDA’s approved list for compounding pharmacies, meaning it cannot legally be compounded into a prescription product in the United States.

What is the desensitization risk?

The KISS1R receptor responds to a pulsing signal, and continuous or overly frequent activation can desensitize it. A related, longer-acting compound tested this directly and found sustained dosing drove testosterone down below castration levels rather than raising it.

What dose was used in the studies?

Doses varied by study and were given as IV infusions or single injections in monitored clinical settings, mostly using kisspeptin-54. Nothing resembling a repeated daily home protocol has ever been tested.

Does kisspeptin help fertility?

It has a real, specific fertility use. Kisspeptin-54 has triggered egg maturation in IVF for women at high OHSS risk, with strong results and a low complication rate in trials, though it remains investigational rather than an approved standard treatment.

Where can I buy kisspeptin?

We recommend Amino Club’s kisspeptin, tested 7 times with full COAs. 10mg is $49.99, about $39.99 with code BRAINFLOW.

The Verdict on Kisspeptin

Kisspeptin earns its reputation as one of the most scientifically significant peptides in reproductive medicine, and it is not close. It sits at the top of the hormone cascade governing puberty, fertility, and sexual function, and unlike most compounds sold in this space, real randomized trials back up its biggest claims. Sexual arousal circuits light up on brain scans in both men and women. It triggers safe, effective egg maturation in IVF. It can restart a reproductive axis that shut down under stress.

The practical version of the science is simple. The dose that shows up everywhere, around 100mcg, lines up with what produced results in trials. The schedule that holds up, spaced out rather than daily, is backed by a real trial built to test exactly that question. Respect the spacing, and this is one of the more exciting peptides in modern endocrinology, full stop.

Kisspeptin and kisspeptin-10 are not FDA-approved for any indication. All information here is for educational and research purposes only and is not medical advice.

Kisspeptin-10 is sold as a research compound for laboratory use only. Consult a qualified healthcare provider before beginning any protocol.

This article contains affiliate links. BrainFlow may earn a commission on qualifying purchases at no additional cost to the reader. We only recommend sources we trust.